Search results for "10036 Medical Clinic"

showing 10 items of 22 documents

Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study

2009

Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C), a rare genetic disorder characterized by progressive neurological deterioration. We report findings from a retrospective observational cohort study assessing the effects of miglustat on neurological disease progression in patients treated in the clinical practice setting. Data from all NP-C patients prescribed miglustat at 25 expert centers were evaluated using a disease disability scale. The scale analyzed four key parameters of neurological disease progression in NP-C (ambulation, manipulation, language, swallowing). Mean individual parameter scores and a co…

MalePediatricsmedicine.medical_specialty1-Deoxynojirimycin1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistryCohort StudiesEndocrinology1311 GeneticsMiglustat1312 Molecular BiologyGeneticsHumansMedicineEnzyme InhibitorsChildMolecular BiologyRetrospective StudiesNiemann–Pick disease type Cbusiness.industryNiemann-Pick Disease Type CRetrospective cohort studymedicine.disease1310 EndocrinologyClinical trial2712 Endocrinology Diabetes and MetabolismTreatment Outcome10036 Medical ClinicCohortFemalebusinessNiemann–Pick diseaseCohort studymedicine.drugMolecular Genetics and Metabolism
researchProduct

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

2018

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the…

MaleRiskmedicine.medical_specialtyCaseinBreastfeeding030209 endocrinology & metabolism610 Medicine & health2700 General MedicineEndocrinology and DiabetesDisease-Free Survivallaw.inventionFollow-Up StudieNutrition Policy03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodSDG 3 - Good Health and Well-beinglawInternal medicineDiabetes mellitusmedicineHumansCumulative incidence030212 general & internal medicineChildInfant Nutritional Physiological PhenomenaOriginal Investigation2. Zero hungerType 1 diabetesbusiness.industryHazard ratioAbsolute risk reductionInfant NewbornCaseinsGeneral Medicineta3121medicine.diseaseInfant Formula3. Good healthDiabetes Mellitus Type 1Infant formula10036 Medical ClinicEndokrinologi och diabetesFemalebusinessHumanFollow-Up Studies
researchProduct

Reading for meaning in dyslexic and young children : distinct neural pathways but common endpoints

2009

Developmental dyslexia is a highly prevalent and specific disorder of reading acquisition characterised by impaired reading fluency and comprehension. We have previously identified fMRI- and ERP-based neural markers of impaired sentence reading in dyslexia that indicated both deviant basic word processing and deviant semantic incongruency processing. However, it remained unclear how specific these impairments are for dyslexia, as they occurred when children with dyslexia (DYS) were compared to chronological age-matched controls (CA) who also differ in the amount of reading experience. Adding a younger control group at a similar reading level (RL) as the dyslexic group, we examined here whic…

MaleTime FactorsWord processingNeuropsychological TestsDyslexiaBehavioral NeuroscienceReading (process)2802 Behavioral NeuroscienceNeural PathwaysImage Processing Computer-AssistedSemantic memoryLanguage disorderChildmedia_commonCerebral CortexBrain Mapping10093 Institute of PsychologyElectroencephalography10058 Department of Child and Adolescent PsychiatryMagnetic Resonance ImagingSemantics10076 Center for Integrative Human PhysiologyFemaleComprehensionPsychologypsychological phenomena and processesSentenceCognitive psychology2805 Cognitive NeuroscienceCognitive Neurosciencemedia_common.quotation_subject610 Medicine & healthExperimental and Cognitive Psychologybehavioral disciplines and activitiesCommunication disordermental disordersReaction TimemedicineHumansAnalysis of Variance3205 Experimental and Cognitive PsychologyDyslexiamedicine.diseaseOxygenReadingReading comprehension10036 Medical Clinic570 Life sciences; biologyEvoked Potentials Visual150 Psychology
researchProduct

Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.

2014

Importance The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins. Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children. Design, Setting, and Participants A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to Ja…

Maleinsulin-Secreting CellsautoantibodiesAutoimmunity2700 General MedicineGastroenterologylaw.invention0302 clinical medicineRandomized controlled trialnewbornlawCaseindouble-blind methodCumulative incidence030212 general & internal medicinehumans: Multidisciplinary general & others [D99] [Human health sciences]childHazard ratioGeneral Medicinefollow-up studiesInfant Formulaanimalscaseinstype 1femaleMilkbreast feedinghydrolysisdiabetes mellitusRiskmedicine.medical_specialty: Multidisciplinaire généralités & autres [D99] [Sciences de la santé humaine]β-cell autoimmunity610 Medicine & health030209 endocrinology & metabolismWeaningArticlehydrolyzed infant formula03 medical and health sciencesInternal medicineDiabetes mellitusHydrolyzed infant formula and early β-cell autoimmunitymedicineanimals; autoantibodies; breast feeding; caseins; child; diabetes mellitus; type 1; dietary proteins; double-blind method; female; follow-up studies; humans; hydrolysis; incidence; infant; newborn; insulin-Secreting Cells; Male; Milk; Risk; Weaning; Autoimmunity; Infant FormulaType 1 diabetesbusiness.industrydietary proteinsta1183Infant Newbornmedicine.diseaseta3123infantDiabetes Mellitus Type 1EndocrinologyInfant formula10036 Medical ClinicincidencebusinessBreast feeding
researchProduct

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)

2012

Abstract Introduction Common symptoms for children with Anderson-Fabry Disease (FD) such as acroparaesthesia and gastrointestinal manifestations can only be objectively assessed in patients using a valid instrument. To date, no such instrument exists. Methods A preliminary 40-item measure of symptoms and experience with FD, the Fabry-specific Paediatric Health and Pain Questionnaire (FPHPQ) was developed, but lacked a formal assessment of its measurement properties. The FPHPQ was used in the Fabry Outcome Survey (FOS), a registry for all patients with a confirmed diagnosis of FD who are receiving agalsidase alfa, or are treatment naïve and who are managed by physicians participating in FOS.…

Malemedicine.medical_specialtyAdolescentIntraclass correlation610 Medicine & healthlcsh:Computer applications to medicine. Medical informaticsSeverity of Illness IndexPsychometrics validationCronbach's alphaQuality of lifeSurveys and QuestionnairesSeverity of illnessmedicineHumansBrief Pain InventoryChildChildrenPain MeasurementFabry diseaseItem analysisbusiness.industryResearchPublic Health Environmental and Occupational HealthReproducibility of ResultsConstruct validity2739 Public Health Environmental and Occupational HealthGeneral MedicinePaediatric Health and Pain Questionnairemedicine.diseaseFabry disease10036 Medical ClinicChild PreschoolEnzyme replacement therapyQuality of LifePhysical therapylcsh:R858-859.7FemalebusinessHealth and Quality of Life Outcomes
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct

Diagnostik und Therapie des Morbus Pompe im Kindesalter

2020

Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced enzyme activity results in abnormal intra- and extralysosomal glycogen deposition as well as impaired cellular function and autophagy. Age at manifestation and severity of disease depend on residual enzyme activity. Enzyme replacement therapy (ERT) is available since 2006. In infantile onset Pompe disease, the most severe form, markedly prolonged survival has resulted in a new phenotype with symptoms and problems not encountered previously. In addition, it became apparent that antibody formation against the recombinant human enzyme may adversely affect the response to ERT. This review summari…

Pediatricsmedicine.medical_specialtybiologybusiness.industryAutophagy030232 urology & nephrologyMedizinGlycogen deposition610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.diseaseEnzyme assay03 medical and health sciences0302 clinical medicine10036 Medical Clinic030225 pediatricsPediatrics Perinatology and Child HealthGlycogen storage disease type IImedicinebiology.proteinbusinessAntibody formation
researchProduct

Hierarchical imaging and computational analysis of three-dimensional vascular network architecture in the entire postnatal and adult mouse brain

2021

The formation of new blood vessels and the establishment of vascular networks are crucial during brain development, in the adult healthy brain, as well as in various diseases of the central nervous system. Here, we describe a step-by-step protocol for our recently developed method that enables hierarchical imaging and computational analysis of vascular networks in postnatal and adult mouse brains. The different stages of the procedure include resin-based vascular corrosion casting, scanning electron microscopy, synchrotron radiation and desktop microcomputed tomography imaging, and computational network analysis. Combining these methods enables detailed visualization and quantification of t…

Vessel networkBiochemistry & Molecular BiologyBrain developmentBrain vasculatureScanning electron microscopeComputer sciencePoint densityCentral nervous systemVascular volumeGenetics and Molecular BiologyINTUSSUSCEPTIVE ANGIOGENESISINHIBITS TUMOR-GROWTHTortuosityBiochemical Research MethodsSCANNING-ELECTRON-MICROSCOPYGeneral Biochemistry Genetics and Molecular BiologyBLOOD-VESSELSSPROUTING ANGIOGENESIS10180 Clinic for NeurosurgeryNEUROVASCULAR UNIT1300 General Biochemistry Genetics and Molecular Biologymedicine10237 Institute of Biomedical EngineeringComputational analysisAdult stageMICROVASCULAR NETWORKSIntussusceptive angiogenesisSprouting angiogenesisScience & TechnologySTRUCTURAL ADAPTATIONCOCHLEAR VASCULATUREMOLECULAR-MECHANISMS10177 Dermatology Clinic10081 Institute of Veterinary Physiology10124 Institute of Molecular Life SciencesVessel diametermedicine.anatomical_structureVascular network10036 Medical ClinicGeneral Biochemistry570 Life sciences; biologyLife Sciences & BiomedicinePerfusionBiomedical engineering
researchProduct

Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany

2015

Enzyme replacement therapy (ERT) has been shown to improve outcome in classical infantile Pompe disease. The purpose of this study was to assess mortality, morbidity, and shortcomings of ERT in a larger cohort of patients treated outside clinical trials. To accomplish this, we retrospectively analyzed the data of all 23 subjects with classical infantile Pompe disease having started ERT in Germany between January 2003 and December 2010.Ten patients (43%) deceased and four others (17%) became ventilator dependent. Seven infants (30.5%) made no motor progress at all, while seven (30.5%) achieved free sitting, and nine (39%) gained free walking. Besides all the seven patients (100%) attaining n…

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtybusiness.industryMEDLINEnutritional and metabolic diseases610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.disease1301 Biochemistry Genetics and Molecular Biology (miscellaneous)ArticleClinical trial2712 Endocrinology Diabetes and Metabolism10036 Medical Clinic2724 Internal MedicineCohortmedicineGlycogen storage diseasebusiness
researchProduct